Ludwig Enterprises publishes ASCO abstract on non-invasive breast cancer mRNA test

LUDWIG ENTERPRISES, INC.

Abstract details mRNA signal from buccal cells combined with machine learning for breast cancer screening.
Study analyzed 48 mRNA cytokine biomarkers from non-invasive cheek swabs across 40 U.S. clinical centers.
Top biomarker system achieved F1-score of 0.9, precision 0.892, recall 0.913 (AUC 0.897).
Second system achieved F1-score of 0.892, precision 0.888, recall 0.902 (AUC 0.849).
Research presented at ASCO 2025 Annual Meeting; previously under embargo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.